来那度胺维持治疗慢性淋巴细胞白血病:CLL6 RESIDUUM研究最终分析
国际多中心III期随机试验纳入143例初始免疫化疗后仍有残留病的CLL患者,来那度胺维持2年较观察延长中位PFS(64.6个月 vs 42.4个月,p=0.039),MRD阴性率更高但总生存无差异,血液学毒性、感染及胃肠道不良反应增加。
要点
- 初始免疫化疗后残留病患者来那度胺维持可延长PFS,获益持续至停药后3年。
- 至少接受20个维持周期者MRD阴性率更高。
- 来那度胺组血液学毒性、感染及胃肠道不良反应更多。
核心结论
- 在初始免疫化疗后存在残留病的CLL患者中,来那度胺维持治疗提高MRD阴性率并延长PFS。
研究设计与样本
- 随机多中心III期试验(ACTRN12610000060044)在澳大利亚和法国开展,比较来那度胺每日维持2年与观察。
- 2011年5月至2018年1月共随机143例,来那度胺组71例,观察组72例。
主要发现
- 中位PFS来那度胺组64.6个月(95%CI 47.7至未达到),观察组42.4个月(95%CI 32.3-61.6),p=0.039。
- 来那度胺获益在维持治疗停止后持续3年。
- 总生存无差异。
- 更多来那度胺组患者达到MRD阴性,尤其是接受至少20个维持周期者。
- 来那度胺导致更多血细胞减少、感染和胃肠道不良反应,未出现急性淋巴细胞白血病病例。
关键数值与推荐
- 主要终点为随机化至疾病进展或死亡的时间。
- 来那度胺维持2年,每日给药。
临床怎么用
- 对初始免疫化疗后仍有残留病的CLL患者,可考虑来那度胺维持以延长PFS并提高MRD阴性率。
- 需权衡血液学毒性、感染及胃肠道不良反应风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of 2 years of daily lenalidomide maintenance versus observation in patients with CLL and residual disease after initial immunochemotherapy. The primary end-point was time to disease progression or death from randomisation. Between May 2011 and January 2018, 143 patients were randomised to receive lenalidomide (n = 71) or observation (n = 72). Median progression-free survival (PFS) was longer with lenalidomide at 64.6 months (95% confidence interval [CI] 47.7 to not reached) versus 42.4 months (95% CI 32.3-61.6) in the observation arm (p = 0.039). Lenalidomide benefit persisted for 3 years after maintenance cessation. There was no difference in overall survival. More patients taking lenalidomide achieved MRD negativity, especially those who received at least 20 maintenance cycles. Lenalidomide led to more cytopenias, infections and gastrointestinal effects. There were no cases of acute lymphoblastic leukaemia. In patients with CLL selected by the presence of residual disease at the end of initial chemoimmunotherapy, lenalidomide maintenance increased the chance of achieving MRD negativity and prolonged PFS.
引用
- Aurran-Schleinitz T, Letestu R, Sartor M, et al. Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups. Br J Haematol. 2026. PMID: 42764148. doi:10.1111/bjh.70850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。